4576.T Stock - D. Western Therapeutics Institute, Inc.
Unlock GoAI Insights for 4576.T
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $471.58M | $428.36M | $448.10M | $414.42M | $355.59M |
| Gross Profit | $424.74M | $391.70M | $420.53M | $394.32M | $338.57M |
| Gross Margin | 90.1% | 91.4% | 93.8% | 95.2% | 95.2% |
| Operating Income | $-1,209,598,000 | $-798,558,000 | $-305,912,000 | $-171,649,000 | $-265,679,000 |
| Net Income | $-1,290,305,000 | $-812,411,000 | $-429,685,000 | $-148,995,000 | $-276,104,000 |
| Net Margin | -273.6% | -189.7% | -95.9% | -36.0% | -77.6% |
| EPS | $-36.74 | $-25.56 | $-14.50 | $-5.08 | $-10.16 |
D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on discovery and development of various drugs. The company offers GLANATEC and GLA-ALPHA, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; DW-1001, an ophthalmic drug; DWR-2206, a regenerative medicine cell-product for bullous keratopathy; and DW-1002, an ophthalmic surgical adjuvant for cataract surgeries, and ILM, ALC, ERM, and PVR membrane staining. It is also developing DW-5LBT, a lidocaine patch for neuropathic pain after shingles; K-321 to treat fuch endothelial corneal dystrophy which is in Phase III clinical trials; and H-1337, a multi-kinase inhibitor that has started Phase IIb clinical trials for the treatment of glaucoma/ocular hypertension. The company was founded in 1999 and is headquartered in Nagoya, Japan.
Visit WebsiteEarnings History & Surprises
4576.TEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 13, 2025 | — | $-3.67 | — | — |
Q3 2025 | Aug 14, 2025 | — | $-3.64 | — | — |
Q2 2025 | May 15, 2025 | — | $-3.41 | — | — |
Q1 2025 | Feb 7, 2025 | — | $-14.24 | — | — |
Q4 2024 | Nov 14, 2024 | — | $-5.66 | — | — |
Q3 2024 | Aug 9, 2024 | — | $-6.18 | — | — |
Q2 2024 | May 13, 2024 | — | $-9.99 | — | — |
Q1 2024 | Feb 9, 2024 | — | $-11.47 | — | — |
Q4 2023 | Nov 10, 2023 | — | $-6.11 | — | — |
Q3 2023 | Aug 10, 2023 | — | $-5.44 | — | — |
Q2 2023 | May 12, 2023 | — | $-3.14 | — | — |
Q1 2023 | Feb 13, 2023 | — | $-6.70 | — | — |
Q4 2022 | Nov 10, 2022 | — | $-3.94 | — | — |
Q3 2022 | Aug 9, 2022 | — | $-3.01 | — | — |
Q2 2022 | May 12, 2022 | — | $-0.74 | — | — |
Q1 2022 | Feb 10, 2022 | — | $-1.60 | — | — |
Q4 2021 | Nov 11, 2021 | — | $-0.64 | — | — |
Q3 2021 | Aug 10, 2021 | — | $-1.42 | — | — |
Q2 2021 | May 13, 2021 | — | $-1.41 | — | — |
Q1 2021 | Feb 12, 2021 | — | $-4.28 | — | — |
Latest News
Frequently Asked Questions about 4576.T
What is 4576.T's current stock price?
What is the analyst price target for 4576.T?
What sector is D. Western Therapeutics Institute, Inc. in?
What is 4576.T's market cap?
Does 4576.T pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to 4576.T for comparison